Coronary Artery Disease with a High Risk of Complications: How to Identify Such Patients and Choose Management Tactics?

Patients with diagnosed coronary artery disease and/or peripheral arterial disease have a high risk of cardiovascular death and disabling vascular events, including stroke, myocardial infarction, and amputation. Secondary prevention in these high-risk patients should include control of modifiable risk factors for the progression of atherosclerosis and antithrombotic therapy to prevent atherothrombosis. Analysis of the literature from the databases PubMed, MEDLINE, HighWire Press was carried out to determine the modern possibilities of assessing the risk of ischemic and hemorrhagic events in a stable course of cardiovascular diseases caused by atherosclerosis, which can be used to determine the categories of patients with the greatest potential benefit from combination antithrombotic therapy. The results of a large randomized study COMPASS, their sub-analyses and the work of other authors, published over the last year, allow us to formulate reasonable conclusions that facilitate the adoption of medical decisions when choosing treatment tactics for patients with a stable course of atherosclerotic cardiovascular diseases. When using low doses of rivaroxaban and aspirin in high-risk groups, the rate of adverse events, including cardiovascular death, myocardial infarction, stroke, and vascular complications of peripheral artery disease, can be significantly reduced. High-risk criteria for severe cardiovascular complications are multifocal atherosclerotic lesions, heart failure, myocardial infarction, diabetes mellitus, or chronic kidney disease. Patients with the highest risk of vascular events will receive the greatest absolute benefit from this treatment. Secondary prevention in patients with chronic coronary syndromes, sinus rhythm and a moderate risk of cardiovascular complications using low doses of rivaroxaban and aspirin is justified, since the ratio of its risk and benefit remains favorable.

1. Fox K.A.A., Metra M., Morais J., Atar D. The myth of 'stable' coronary artery disease. Nat Rev Cardiol. 2020;17(1):9-21. DOI:10.1038/s41569-019-0233-y.

2. Ma T.T., Wong I.C.K., Man K.K.C., et al. Effect of evidence-based therapy for secondary prevention of cardiovascular disease: Systematic review and meta-analysis. PLoS One. 2019;14(1):e0210988. DOI:10.1371/journal.pone.0210988.

3. Eikelboom J.W., Connolly S.J., Bosch J., et al.; for the COMPASS Investigators. Rivaroxaban with or without aspirin in stable cardiovascular disease. N Engl J Med. 2017;377(14):1319-30. DOI:10.1056/NEJMoa1709118.

4. Anand S.S., Bosch J., Eikelboom J.W., et al.; on behalf of the COMPASS Investigators. Rivaroxaban with or without aspirin in patients with stable peripheral or carotid artery disease: an international, randomised, doubleblind, placebo-controlled trial. Lancet. 2018;391(10117):219-29. DOI:10.1016/S0140-6736(17)32409-1.

5. Connolly S.J., Eikelboom J.W., Bosch J., et al. on behalf of the COMPASS investigators. Rivaroxaban with or without aspirin in patients with stable coronary artery disease: an international, randomised, double-blind, placebo-controlled trial. Lancet. 2018;391(10117):205-18. DOI:10.1016/S0140-6736(17)32458-3.

6. Sanmartm M., Bellmunt S., Cosm-Sales J., et al. Role of rivaroxaban in the prevention of atherosclerotic events. Expert Rev Clin Pharmacol. 2019;12(8):771-80. DOI:10.1080/17512433.2019.1637732.

7. Antithrombotic Trialists' (ATT) Collaboration, Baigent C., Blackwell L., Collins R., et al. Aspirin in the primary and secondary prevention of vascular disease: collaborative meta-analysis of individual participant data from randomised trials. Lancet. 2009;373(9678):1849-60. DOI:10.1016/S0140-6736(09)60503-1.

8. Cholesterol Treatment Trialists' (CTT) Collaboration, Fulcher J., O'Connell R., Voysey M., et al. Efficacy and safety of LDL-lowering therapy among men and women: meta-analysis of individual data from 174,000 participants in 27 randomised trials. Lancet. 2015;385(9976):1397-405. DOI:10.1016/S0140-6736(14)61368-4.

9. Collins R., Reith C., Emberson J., et al. Interpretation of the evidence for the efficacy and safety of statin therapy. Lancet. 2016;388(9976):2532-61. DOI:10.1016/S0140-6736(14)61368-4.

10. Ettehad D., Emdin C.A., Kiran A., et al. Blood pressure lowering for prevention of cardiovascular disease and death: a systematic review and meta-analysis. Lancet. 2016;387(10022):957-67. DOI:10. 1016/S0140-6736(15)01225-8.

11. Dagenais G.R., Pogue J., Fox K., et al. Angiotensin-converting-enzyme inhibitors in stable vascular disease without left ventricular systolic dysfunction or heart failure: a combined analysis of three trials. Lancet. 2006;368(9535):581-88. DOI:10.1016/S0140-6736(06)69201-5.

12. Cowie M.R., Lamy A., Levy P., et al. Health economic evaluation of rivaroxaban in the treatment of patients with chronic coronary artery disease or peripheral artery disease. Cardiovasc Res. 2019 Nov 28;cvz278. doi: 10.1093/cvr/cvz278. Online ahead of print.

13. Pogosova N.V., Panov A.V., Kulikov A.Yu., et al. Pharmacoeconomic study of rivaroxaban and acetylsalicylic acid combination use in patients with coronary artery disease and/or peripheral artery disease. Russian Journal of Cardiology. 2019;24(12):76-86 (In Russ.). DOI:10.15829/1560-4071-2019-12-76-86.

14. Kruger P.C., Guzik T.J., Eikelboom J.W. How can the results of the COMPASS trial benefit patients with coronary or peripheral artery disease in Poland? Kardiol Pol. 2019;77(7-8):661-69. DOI:10.33963/KP.14855.

15. Bosch J., Eikelboom J.W., Connolly S.J., et al. Rationale, Design and Baseline Characteristics of Participants in the Cardiovascular Outcomes for People Using Anticoagulation Strategies (COMPASS) Trial. Can J Cardiol. 2017;33(8):1027-35. DOI:10.1016/j.cjca.2017.06.001.

16. Anand S.S., Eikelboom J.W., Dyal L., et al. Rivaroxaban Plus Aspirin Versus Aspirin in Relation to Vascular Risk in the COMPASS Trial. J Am Coll Cardiol. 2019;73(25):3271-80. DOI:10.1016/j.jacc.2019.02.079.

17. Darmon A., Sorbets E., Ducrocq G., et al. Association of Multiple Enrichment Criteria With Ischemic and Bleeding Risks Among COMPASS-Eligible Patients. J Am Coll Cardiol. 2019;73(25):3281-91. DOI:10.1016/j.jacc.2019.04.046.

18. Kruger P.C., Guzik T.J., Eikelboom J.W. How Can the Results of the COMPASS Trial Benefit Patients with Coronary or Peripheral Artery Disease in Poland? Kardiol Pol. 2019;77(7-8):661-9. DOI:10.33963/KP.14855.

19. Branch K.R., Probstfield J.L., Eikelboom J.W., et al. Rivaroxaban with or Without Aspirin in Patients with Heart Failure and Chronic Coronary or Peripheral Artery Disease. Circulation. 2019;140(7):529-537. DOI:10.1161/CIRCULATIONAHA.119.039609.

20. Fox K.A.A., Eikelboom J.W., Shestakovska O., et al. Rivaroxaban Plus Aspirin in Patients With Vascular Disease and Renal Dysfunction: From the COMPASS Trial. J Am Coll Cardiol. 2019;73(18):2243-50. DOI:10.1016/j.jacc.2019.02.048.

21. Wilson P.W., D'Agostino R. Sr., Bhatt D.L., et al. An international model to predict recurrent cardiovascular disease. Am J Med. 2012;125(7):695-703. DOI:10.1016/j.amjmed.2012.01.014.

22. Hothorn T., Hornik K., Zeileis A. Unbiased recursive partitioning: a conditional inference framework. J Comput Graph Stat. 2006;15:651-74. DOI:10.1198/106186006X133933.

23. Vanassche T., Verhamme P., Anand S.S., et al. Risk factors and clinical outcomes in chronic coronary and peripheral artery disease: An analysis of the randomized, double-blind COMPASS trial. Eur J Prev Cardiol. 2020;27(3):296-307. DOI:10.1177/2047487319882154.

24. Eikelboom J.W., Bosch J.J., Connolly S.J., et al. Major Bleeding in Patients With Coronary or Peripheral Artery Disease Treated With Rivaroxaban Plus Aspirin. J Am Coll Cardiol. 2019;74(12):1519-28. DOI:10.1016/j.jacc.2019.07.065.

25. Ducrocq G., Wallace J.S., Baron G., et al. Risk score to predict serious bleeding in stable outpatients with or at risk of atherothrombosis. Eur Heart J. 2010;31(10):1257-65. DOI:10.1093/eurheartj/ehq021.

26. Knuuti J., Wijns W., Saraste A., et al. 2019 ESC Guidelines for the diagnosis and management of chronic coronary syndromes. Eur Heart J. 2020;41(3):407-77. DOI:10.1093/eurheartj/ehz425.

27. Ezekowitz M.D., Reilly P.A., Nehmiz G., et al. Dabigatran with or without concomitant aspirin compared with warfarin alone in patients with nonvalvular atrial fibrillation (PETRO Study). Am J Cardiol. 2007;100(9):1419-26. DOI:10.1016/j.amjcard.2007.06.034.

28. Kent D.M., Steyerberg E., van Klaveren D. Personalized evidence based medicine: predictive approaches to heterogeneous treatment effects. BMJ. 2018;363:k4245. DOI:10.1136/bmj.k4245.

29. de Vries T.I., Eikelboom J.W., Bosch J., et al. Estimating individual lifetime benefit and bleeding risk of adding rivaroxaban to aspirin for patients with stable cardiovascular disease: results from the COMPASS trial. Eur Heart J. 2019;40(46):3771-78. DOI:10.1093/eurheartj/ehz404.

30. Chao T.F., Liao J.N., Tuan T.C., et al. Incident co-morbidities in patients with atrial fibrillation initially with a CHA2DS2-VASc score of 0 (males) or 1 (females): implications for reassessment of stroke risk in initially ‘low-risk' patients. Thromb Haemost. 2019;119(7):1162-70. DOI:10.1055/s-0039-1683933.

31. Capodanno D. Risk stratification with the DAPT score: carefully read the instructions and use as intended. Thromb Haemost. 2017;117(10):1836-9. DOI:10.1160/TH17-07-0495.

32. Desperak P., Hudzik B., G^sior M. Assessment of patients with coronary artery disease who may benefit from the use of rivaroxaban in the real world: implementation of the COMPASS trial criteria in the TERCET registry population. Pol Arch Intern Med. 2019;129(7-8):460-68. DOI:10.20452/pamw.14907.

33. Dyrbus K., Osadnik T, Desperak P, et al. Evaluation of dyslipidaemia and the impact of hypolipidemic therapy on prognosis in high and very high risk patients through the Hyperlipidaemia Therapy in tERtiary Cardiological cEnTer (TERCET) Registry. Pharmacol Res. 2018;132:204-10. DOI:10.1016/j.phrs.2017.12.015.

34. Puymirat E., Schiele F., Zeller M., et al. Do randomized clinical trial selection criteria reflect levels of risk as observed in a general population of acute myocardial infarction survivors? The PEGASUS trial in the light of the FAST-MI 2005 registry. Int J Cardiol. 2016;223:604-10. DOI:10.1016/j.ij-card.2016.08.191.

35. Maron D.J., Hochman J.S., Reynolds H.R., et al. Initial Invasive or Conservative Strategy for Stable Coronary Disease. N Engl J Med. 2020;382(15):1395-1407. DOI:10.1056/NEJMoa1915922.

36. Bonaca M.P., Bhatt D.L., Cohen M., et al. Long-term use of ticagrelor in patients with prior myocardial infarction. N Engl J Med. 2015;372(19):1791-800. DOI:10.1056/NEJMoa1500857.

37. Bradley S.M., Hess G.P., Stewart P., et al. Implications of the PEGASUS-TIMI 54 trial for US clinical practice. Open Heart. 2017;4(1):e000580. DOI:10.1136/openhrt-2016-000580.

38. De Luca L., Piscione F., Colivicchi F. et al. Contemporary management of patients referring to cardiologists one to three years from a myocardial infarction: The EYESHOT Post-MI study. Int J Cardiol. 2018;273:8-14. DOI:10.1016/j.ijcard.2018.08.055.

39. Connolly S.J., Eikelboom J.W., Bosch J., et al. Rivaroxaban with or without aspirin in patients with stable coronary artery disease: an international, randomised, double-blind, placebo-controlled trial. Lancet. 2018;391(10117):205-18. DOI:10.1016/S0140-6736(17)32458-3.

40. Steg P.G., Bhatt D.L., Simon T., et al. Ticagrelor in Patients with Stable Coronary Disease and Diabetes. N Engl J Med. 2019;381(14):1309-20. DOI:10.1056/NEJMoa1908077.

41. Kanorskii S.G., Vasuk Y.A., Gridasova R.A., et al. Treatment of Patients with Stable Manifestations of Atherosclerotic Vascular Disease: New Possibilities (Conclusion of the Council of Experts from November 16, 2018, Rostov-on-Don). Kardiologiia. 2019;59(9):97-100 (In Russ.)